Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
University of Oklahoma
Emory University
Mayo Clinic
Mayo Clinic
Albert Einstein College of Medicine
Abramson Cancer Center at Penn Medicine